| Similar Articles |
|---|
 |
The Motley Fool
July 26, 2007
Brian Lawler |
Flamel Gets Stomped by GSK Shares of Flamel fall as its partner doesn't focus on marketing its lead drug.   |
The Motley Fool
February 11, 2008
Brian Lawler |
No Fire Fueling Flamel's Top Drug Flamel Technologies had a rough 2007; and with only one drug determining its near-term success, investors should be cautious of this drugmaker. |
The Motley Fool
October 25, 2007
Brian Lawler |
Flamel Gets Upbeat News About Coreg Flamel Technologies is earning more than had been calculated from its lead drug, but the company still isn't profitable. Investors, take note. |
The Motley Fool
May 14, 2007
Brian Lawler |
Just the Beginning for Flamel? The drug developer released first-quarter financial results and updated investors on the progress of its newly marketed Coreg CR compound. Investors, take note. |
The Motley Fool
August 27, 2007
Rich Duprey |
Flamel Falls Out of Compliance Market lashes out after a patient-compliance study shows that its only drug offers no better solution. Flamel has always been a risky investment, and that hasn't changed. |
The Motley Fool
August 3, 2007
Brian Lawler |
Flamel Cooked When a drugmaker's future is highly dependent on one product, shares are bound to take a hit if that product isn't living up to expectations. Such was the case with Flamel Technologies. |
The Motley Fool
March 5, 2008
Brian Lawler |
Flamel in a Nutshell After a choppy year, Flamel says there are plenty of new possibilities in its pipeline. |
The Motley Fool
November 2, 2007
Brian Lawler |
Flamel Plays Close to the Vest With only one sustainable source of revenue, the drug developer tries to curtail spending and get new compounds into the pipeline. Investors, take note. |
The Motley Fool
September 14, 2007
Brian Lawler |
Is Flamel Catching On? Flamel Technologies announces a deal with Wyeth to develop an improved formulation of a drug, but the financials, and details, remain secret. |
The Motley Fool
August 8, 2008
Brian Lawler |
Flamel Tries to Get It in Gear Flamel has done a good job of reducing its cash burn, allowing it to buy some time to work on the compounds in its pipeline. |
The Motley Fool
December 18, 2006
Brian Lawler |
Nice: Flamel's Drug Approval With so much pessimism and internal hullabaloo, there weren't many investors willing to stick with Flamel, but those who did have been rewarded nicely. |
The Motley Fool
April 28, 2008
Brian Lawler |
Flamel Inches Forward New sales data arrives for one lead drug, new promising data for another. |
The Motley Fool
October 26, 2007
Brian Lawler |
Another Prospect for Flamel The drug developer's good week continues with favorable news about a treatment for hepatitis C. Investors, take note. |
Chemistry World
September 24, 2010
Andrew Turley |
End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use. |
The Motley Fool
March 15, 2011
Brian Orelli |
Extending the Competition in Parkinson's Disease Impax's extended-release drug looks good. |
The Motley Fool
May 15, 2008
Brian Lawler |
What's Cooking at Flamel? The drugmaker makes finding partners to help pay for its hepatitis C and diabetes compounds a top priority. |
The Motley Fool
November 15, 2007
Brian Lawler |
Flamel Now Part of Wacky Lawsuit Hijinks Multiple class action shareholder lawsuits targeting Flamel Technologies are announced, following a failed study of the company's lead drug. |
The Motley Fool
October 25, 2005
Jason Mac Gurn |
Visualizing Value for Flamel Those interested in the long-term potential of this biotech's business should be searching for signs that its technological potential will evolve to provide value for shareholders. |
The Motley Fool
April 17, 2008
Brian Orelli |
Headache Over for Pozen and Glaxo? The duo's FDA headache regarding their migraine drug is over, but a new one is about to begin. |
The Motley Fool
October 25, 2007
Brian Lawler |
Rope-a-Dope at GSK? Following the negative FDA panel hearings and safety review of diabetes drug Avandia and exchange rate movements against it, revenue fell 3% in the third quarter for GlaxoSmithKline. Operating income and profit were also slightly down. |
Chemistry World
February 26, 2010
Sarah Houlton |
Report hits out at GSK's Avandia GlaxoSmithKline's diabetes drug Avandia (rosiglitazone) has been dealt another blow, with the publication of a report by two US senators claiming the company knew about safety problems long before they reached the public domain. |
The Motley Fool
June 3, 2011
Frank Vinluan |
GSK Sees Positive Results on Asthma, COPD Drug Expected to Succeed Advair GSK gets good news. |
The Motley Fool
May 28, 2008
Brian Lawler |
A Little-Noticed Drug Rejection The EU temporarily blocks Sanofi and Bristol-Myers' shot at extending a drug's lifespan. |
The Motley Fool
April 5, 2011
Frank Vinluan |
GSK in Emerging Markets: Why Sales Staff There Are Key to Global Strategy GlaxoSmithKline's rivalry with top drug companies such as Pfizer goes beyond the products they sell. In some emerging markets, it now also extends to the staff they're fighting to keep. |
The Motley Fool
June 14, 2007
Brian Lawler |
Dueling Fools: GlaxoSmithKline Bull Shares of the pharmaceutical may be temporarily down, but it's not out. |
The Motley Fool
October 26, 2006
Brian Lawler |
Glaxo's Prescription for Sagging Sales Trading at roughly 32 times its trailing-12-month earnings, and with a solid 2.9% dividend yield, GSK is a fine investment for shareholders patient enough to wait until 2008 for a return to solid revenue growth. |
Chemistry World
October 17, 2012
Maria Burke |
GSK pledge on trials transparency GlaxoSmithKline has announced a series of initiatives to make clinical trial data publically available that could set a precedent in an industry not known for its transparency. |
The Motley Fool
January 19, 2011
Cliff D'Arcy |
Glaxo Stung by Legal Bill GSK shareholders are hit by costly legal settlements. |
The Motley Fool
September 15, 2011
Frank Vinluan |
GSK's New Drug Marketing Model: Pharma Reps As Educators, Not Sellers The conversation between sales reps and doctors today is vastly different compared to one year ago. |
Chemistry World
June 14, 2013
Sarah Houlton |
GSK fires Chinese R&D head in data investigation GSK's research head in China has been sacked after claims of misrepresented data in a research paper. The company has asked the journal, Nature Medicine, to retract the paper. |
The Motley Fool
August 27, 2007
Brian Lawler |
Cephalon Makes A Deal The newest drug in its cabinet is expected to hit the U.S. market in the fourth quarter. Investors will know relatively soon whether Cephalon pulled off another coup or just flushed $100 million down the toilet. |
Chemistry World
April 23, 2014
Phillip Broadwith |
GSK corruption investigation widens Pharma giant GlaxoSmithKline has responded to allegations made by the BBC's Panorama program concerning improper conduct by GSK's sales staff in Poland. |
The Motley Fool
June 15, 2005
Charly Travers |
Flamel's CEO Must Go Because the biotech firm has disappointed, investors have understandably not rewarded its lousy results. Flamel's shareholders must vote to remove a management road block to the company's success. |
The Motley Fool
November 26, 2007
Brian Lawler |
Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year. |
BusinessWeek
October 4, 2004
Kerry Capell |
Why Glaxo Can't Shake the Flu Sales are weakening as hot sellers come off-patent. But the pipeline looks healthy. And there's the rub. Just when GSK's image is at a new low, its prospects are improving. |
The Motley Fool
November 9, 2006
Brian Lawler |
The Best Blue Chip for 2007: GlaxoSmithKline Here's a blue-chip pharma stock for your portfolio. |
The Motley Fool
April 28, 2005
Stephen D. Simpson |
Glaxo Works to Stay on Track With FDA issues near resolution, Glaxo should continue its respectable growth trajectory. Investors looking at the pharmaceutical space would do well to at least consider this stock. |
Chemistry World
April 19, 2013
Phillip Broadwith |
Objections raised to GSK pay-for-delay deals The UK Office of Fair Trading has said that GlaxoSmithKline's deals to delay generic drugs infringed competition laws. |
Chemistry World
April 9, 2014
Emma Stoye |
GSK investigates bribery claims in the Middle East GlaxoSmithKline has been accused of bribing doctors and healthcare officials in Iraq in emails leaked to the Wall Street Journal by a whistleblower. |
The Motley Fool
April 15, 2011
Frank Vinluan |
GSK to Shed Weight Loss Drug alli and 18 Others GSK wants to focus on fast-growing "priority brands." |
BusinessWeek
March 6, 2006
Gene G. Marcial |
Why Glaxo Looks More Robust Big pharma, besieged by generic rivals, is hardly a Street favorite. But GlaxoSmithKline may be an exception. |
Chemistry World
December 5, 2014
Andy Extance |
GSK cuts US jobs in push for savings 350 of the chemists, engineers and other roles will be lost by April 2015, another 450 by July, and the remainder eliminated by the end of the year. |
The Motley Fool
March 4, 2005
Rich Duprey |
Flamel Flames Out Again Nanotech regains rights to herpes treatment as partnership with pharma Biovail fails. |
